Table 47 (abstract P166). See text for description
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one
Etanercept | Tocilizumab | IL-1i | ||
|---|---|---|---|---|
N = 143 | n = 72 | N = 55 | ||
Baseline | JADAS10 Median (IQR) | 8.2 (5.3–13.0) | 9.6 (4.9–13.3) | 8.2 (5.1–13.3) |
Month 6 | JADAS10 Median (IQR) | 6.2(1.1–15.6) | 0.8 (0.1–5.3) | 6.6 (0.2–2.0) |
JADAS MDA n (%) | 26 (29.5%) | 21 (61.8%) | 21 (65.6%) | |
JADAS Remission n (%) | 16 (18.2%) | 15 (44.1%) | 16 (50%) | |
Discontinuations (< Month 6) | Inefficacy (n, %) | 23 (26.1%) | 4 (11.8%) | 7 (21.9%) |
Intolerance (n, %) | 1 (2.9%) | |||
Remission (n, %) | 1 (1.1%) | |||